Key result
β-CD-DPPE-Dox nanomedicine inhibits tumor growth and induces apoptosis versus Dox alone in murine hepatoma.
Why the study?
The development of β-CD-DPPE-Dox nanomedicine aims to improve water solubility and controlled release of Doxorubicin for enhanced anticancer and antitumor effects.
β-CD-DPPE-Dox nanomedicine offers a promising pH-sensitive delivery system for doxorubicin with potentially reduced toxicity and preserved antitumor efficacy.
and the DPPE molecule, and its' water-solubility was more excellent than the traditional phospholipid molecule. The spherical micelles was formed by β-CD-DPPE molecule in aqueous solution, and the β-CD-DPPE-Dox nanomedicine can be prepared through loading Dox (Doxorubicin) into the micelles, and the Dox loading ratio was about 82.3 ± 7.27%. At the same time the Dox release behavior from the nanomedicine was sustained-release and pH controlled release, and the release test in vitro showed that the release rate of the Dox at the lower pH was faster than that of normal pH (pH = 7.4), which indicated that the rate of release in the tumor microenvironment is faster than in the normal tissue. Biological test showed that the micelles was low cytotoxicity, and the cytotoxicity of β-CD-DPPE-Dox nanomedicine was lower than the Dox under the same Dox concentration, and the β-CD-DPPE-Dox nanomedicine could effectively induce cancer cell apoptosis and inhibit the tumor growth.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2019) studied Hepatoma (H22 murine hepatoma) (n=12). β-CD-DPPE-Dox nanomedicine vs. PBS and β-CD-DPPE micelles was evaluated on Tumor volume. β-CD-DPPE-Dox nanomedicine significantly inhibited tumor growth and induced cancer cell apoptosis in a murine hepatoma model without affecting body weight.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: